ArticleJCO oncology advances2025

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

Damon R Reed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.